<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03887650</url>
  </required_header>
  <id_info>
    <org_study_id>HHC-2018-0231</org_study_id>
    <nct_id>NCT03887650</nct_id>
  </id_info>
  <brief_title>LIBERATE - LIposomal Bupivacaine vERsus Adjuncts in Total shouldErs</brief_title>
  <official_title>LIBERATE - LIposomal Bupivacaine vERsus Adjuncts in Total shouldErs: A Randomized Controlled Trial of Injection at the Brachial Plexus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hartford Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hartford Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a single-center, prospective, randomized controlled cross-sectional study
      comparing interscalene brachial plexus block with liposomal bupivacaine versus bupivacaine
      with epinephrine and PF dexamethasone in patients undergoing primary shoulder arthroplasty.
      Primary endpoint will be total opioid consumption in the first three post-operative days.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>single-center, prospective, randomized controlled cross-sectional study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total opioid consumption for the first three postoperative days (PODs) after TSA, standardized to morphine milligram equivalents (MMEs)</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first opioid medication</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessment at post anesthesia care unit (PACU) arrival, PACU discharge, POD #1, POD #2, POD #4, and POD #60</measure>
    <time_frame>60 days</time_frame>
    <description>using questions from the Modified Brief Pain Inventory (MBPI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length-of-stay</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of patient overall satisfaction with pain control</measure>
    <time_frame>60 days</time_frame>
    <description>on a scale from 0 = very dissatisfied to 10 = very satisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of distress from block numbness</measure>
    <time_frame>60 days</time_frame>
    <description>on a scale of 0 to 10 with 0 = not at all and 10 = very much (adapted from the Overall Benefit of Analgesia Score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of sensory and motor nerve block</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Notation of adverse postoperative events or block complications up to 60 days after surgery including:</measure>
    <time_frame>60 days</time_frame>
    <description>Postoperative nausea/vomiting (PONV), as defined by non-prophylactic administration of antiemetics during hospital stay within 24 hours post-operation
Local anesthetic systemic toxicity (LAST) as defined by any treatment for this condition during hospital admission
Postoperative neurologic symptoms (PONS) as defined as sensory or motor dysfunction in appropriate anatomic distribution of block present at &gt; 4 days post-surgery
Postoperative ED visit or readmission due to uncontrolled pain within 60 postoperative days
Bleeding/hematoma at the site of local anesthetic injection that develops prior to discharge from the hospital
Hospital readmission within 30 days from discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Post-operative Pain</condition>
  <condition>Total Shoulder Arthroplasty</condition>
  <condition>Osteoarthritis of the Shoulder</condition>
  <condition>Pain Management</condition>
  <arm_group>
    <arm_group_label>Liposomal Bupivacaine 1.3%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10mL Liposomal Bupivacaine 1.3% (133 mg) mixed with 10mL of 0.5% Bupivacaine (total volume 20mL) in single injection interscalene brachial plexus block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine 0.5% with Adjuncts</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20mL 0.5% Bupivacaine with 5 mg PF dexamethasone and 5 mcg epinephrine (total volume 20.5mL) in single injection interscalene brachial plexus block</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Bupivicaine 1.3%</intervention_name>
    <description>10mL Liposomal Bupivacaine 1.3% (133 mg) mixed with 10mL of 0.5% Bupivacaine (total volume 20mL) in single injection interscalene brachial plexus block</description>
    <arm_group_label>Liposomal Bupivacaine 1.3%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine 0.5%</intervention_name>
    <description>20mL 0.5% Bupivacaine with 5 mg PF dexamethasone and 5 mcg epinephrine (total volume 20.5mL) in single injection interscalene brachial plexus block</description>
    <arm_group_label>Bupivacaine 0.5% with Adjuncts</arm_group_label>
    <other_name>epinephrine</other_name>
    <other_name>dexamethasone preservative-free</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient age &gt;18 years;

          -  Lack of language barrier;

          -  Informed consent obtained;

          -  Presenting for primary total shoulder arthroplasty (TSA), both anatomic and reverse,
             by a specialty-trained surgeon;

          -  American Society of Anesthesiology (ASA) physical status score I- III

        Exclusion Criteria:

          -  Presence of a language barrier;

          -  Inability to complete telephone and/or paper questionnaire;

          -  Lack of consent;

          -  Allergy to local anesthetic;

          -  Chronic pain syndrome and/or preoperative opioid use &gt; 50 MME per day (including
             extended-release formulations and methadone);

          -  Preoperative consultation to chronic pain service;

          -  History of (&lt;3 months) or current substance abuse, including any illicit drugs or
             excessive alcohol consumption as defined by the Office of Disease Prevention and
             Health Promotion (4 or more drinks per day or 8 or more drinks per week for women and
             5 or more drinks per day or 15 or more drinks per week for men);

          -  Baseline peripheral neuropathy of the brachial plexus;

          -  Contraindication to receiving single shot peripheral nerve blockade; including
             antithrombotic medications as per most recent American Society of Regional - -
             -Anesthesiology (ASRA) guidelines 17 , coagulopathy or coagulation disorder, or
             infection at injection site;

          -  Severe chronic obstructive pulmonary disease (COPD) or other significant pulmonary
             disease where interscalene nerve block would be contraindicated due to concern for
             respiratory failure from phrenic nerve palsy;

          -  Weight &lt; 45 kg, given concern for local anesthetic toxicity at dosages given for the
             study; ASA score IV-V;

          -  Revision arthroplasty;

          -  Anatomic abnormality that limits or prevents the patient from receiving an
             interscalene nerve block;

          -  Pregnant, nursing, or planning to become pregnant during the study or within 1 month
             after the shoulder replacement surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Sposito, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hartford Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bethany Samperi</last_name>
    <phone>860-972-5978</phone>
    <email>bethany.samperi@hhchealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carla Maffeo-Mitchell, MD</last_name>
    <email>Carla.Maffeo-Mitchell@hhchealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Bone and Joint Institute at Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Sposito, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Brummett CM, Waljee JF, Goesling J, Moser S, Lin P, Englesbe MJ, Bohnert ASB, Kheterpal S, Nallamothu BK. New Persistent Opioid Use After Minor and Major Surgical Procedures in US Adults. JAMA Surg. 2017 Jun 21;152(6):e170504. doi: 10.1001/jamasurg.2017.0504. Epub 2017 Jun 21. Erratum in: JAMA Surg. 2019 Mar 1;154(3):272.</citation>
    <PMID>28403427</PMID>
  </reference>
  <reference>
    <citation>Vieira PA, Pulai I, Tsao GC, Manikantan P, Keller B, Connelly NR. Dexamethasone with bupivacaine increases duration of analgesia in ultrasound-guided interscalene brachial plexus blockade. Eur J Anaesthesiol. 2010 Mar;27(3):285-8. doi: 10.1097/EJA.0b013e3283350c38.</citation>
    <PMID>20009936</PMID>
  </reference>
  <reference>
    <citation>Movafegh A, Razazian M, Hajimaohamadi F, Meysamie A. Dexamethasone added to lidocaine prolongs axillary brachial plexus blockade. Anesth Analg. 2006 Jan;102(1):263-7.</citation>
    <PMID>16368840</PMID>
  </reference>
  <reference>
    <citation>Parrington SJ, O'Donnell D, Chan VW, Brown-Shreves D, Subramanyam R, Qu M, Brull R. Dexamethasone added to mepivacaine prolongs the duration of analgesia after supraclavicular brachial plexus blockade. Reg Anesth Pain Med. 2010 Sep-Oct;35(5):422-6. doi: 10.1097/AAP.0b013e3181e85eb9.</citation>
    <PMID>20814282</PMID>
  </reference>
  <reference>
    <citation>Rasmussen SB, Saied NN, Bowens C Jr, Mercaldo ND, Schildcrout JS, Malchow RJ. Duration of upper and lower extremity peripheral nerve blockade is prolonged with dexamethasone when added to ropivacaine: a retrospective database analysis. Pain Med. 2013 Aug;14(8):1239-47. doi: 10.1111/pme.12150. Epub 2013 Jun 11.</citation>
    <PMID>23755801</PMID>
  </reference>
  <reference>
    <citation>McLaughlin DC, Cheah JW, Aleshi P, Zhang AL, Ma CB, Feeley BT. Multimodal analgesia decreases opioid consumption after shoulder arthroplasty: a prospective cohort study. J Shoulder Elbow Surg. 2018 Apr;27(4):686-691. doi: 10.1016/j.jse.2017.11.015. Epub 2018 Jan 3.</citation>
    <PMID>29305103</PMID>
  </reference>
  <reference>
    <citation>Candiotti K. Liposomal bupivacaine: an innovative nonopioid local analgesic for the management of postsurgical pain. Pharmacotherapy. 2012 Sep;32(9 Suppl):19S-26S. doi: 10.1002/j.1875-9114.2012.01183.x.</citation>
    <PMID>22956491</PMID>
  </reference>
  <reference>
    <citation>Abildgaard JT, Lonergan KT, Tolan SJ, Kissenberth MJ, Hawkins RJ, Washburn R 3rd, Adams KJ, Long CD, Shealy EC, Motley JR, Tokish JM. Liposomal bupivacaine versus indwelling interscalene nerve block for postoperative pain control in shoulder arthroplasty: a prospective randomized controlled trial. J Shoulder Elbow Surg. 2017 Jul;26(7):1175-1181. doi: 10.1016/j.jse.2017.03.012. Epub 2017 May 4.</citation>
    <PMID>28479257</PMID>
  </reference>
  <reference>
    <citation>Hannan CV, Albrecht MJ, Petersen SA, Srikumaran U. Liposomal Bupivacaine vs Interscalene Nerve Block for Pain Control After Shoulder Arthroplasty: A Retrospective Cohort Analysis. Am J Orthop (Belle Mead NJ). 2016 Nov/Dec;45(7):424-430.</citation>
    <PMID>28005096</PMID>
  </reference>
  <reference>
    <citation>Wang K, Zhang HX. Liposomal bupivacaine versus interscalene nerve block for pain control after total shoulder arthroplasty: A systematic review and meta-analysis. Int J Surg. 2017 Oct;46:61-70. doi: 10.1016/j.ijsu.2017.08.569. Epub 2017 Aug 24. Review.</citation>
    <PMID>28843463</PMID>
  </reference>
  <reference>
    <citation>Schroer WC, Diesfeld PG, LeMarr AR, Morton DJ, Reedy ME. Does Extended-Release Liposomal Bupivacaine Better Control Pain Than Bupivacaine After Total Knee Arthroplasty (TKA)? A Prospective, Randomized Clinical Trial. J Arthroplasty. 2015 Sep;30(9 Suppl):64-7. doi: 10.1016/j.arth.2015.01.059. Epub 2015 Jun 3.</citation>
    <PMID>26117072</PMID>
  </reference>
  <reference>
    <citation>Vandepitte C, Kuroda M, Witvrouw R, Anne L, Bellemans J, Corten K, Vanelderen P, Mesotten D, Leunen I, Heylen M, Van Boxstael S, Golebiewski M, Van de Velde M, Knezevic NN, Hadzic A. Addition of Liposome Bupivacaine to Bupivacaine HCl Versus Bupivacaine HCl Alone for Interscalene Brachial Plexus Block in Patients Having Major Shoulder Surgery. Reg Anesth Pain Med. 2017 May/Jun;42(3):334-341. doi: 10.1097/AAP.0000000000000560.</citation>
    <PMID>28157791</PMID>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 21, 2019</study_first_submitted>
  <study_first_submitted_qc>March 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2019</study_first_posted>
  <last_update_submitted>March 25, 2019</last_update_submitted>
  <last_update_submitted_qc>March 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hartford Hospital</investigator_affiliation>
    <investigator_full_name>Jennifer Sposito, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Brachial Plexus</keyword>
  <keyword>Liposomal Bupivacaine</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Interscalene</keyword>
  <keyword>Bupivacaine</keyword>
  <keyword>Shoulder Arthroplasty</keyword>
  <keyword>Regional anesthesia</keyword>
  <keyword>Exparel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

